Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-11-29

Clinical Trial Update: MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 MRI study update of BAY 43-9006 in metastatic renal cell carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BAY 43-9006 (sorafenib)

Snippet

Sponsor: University of Chicago | Conditions: Metastatic Renal Cell Carcinoma | Phase 3 | Status: COMPLETED